PT  - JOURNAL ARTICLE
AU  - Rachel E. Baker
AU  - Wenchang Yang
AU  - Gabriel A. Vecchi
AU  - C. Jessica E. Metcalf
AU  - Bryan T. Grenfell
TI  - Assessing the influence of climate on future wintertime SARS-CoV-2 outbreaks
AID  - 10.1101/2020.09.08.20190918
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.08.20190918
4099  - http://medrxiv.org/content/early/2020/09/10/2020.09.08.20190918.short
4100  - http://medrxiv.org/content/early/2020/09/10/2020.09.08.20190918.full
AB  - High susceptibility has limited the role of the climate in the SARS-CoV-2 pandemic to date. However, understanding a possible future effect of climate, as susceptibility declines and the northern-hemisphere winter approaches, is an important open question. Here we use an epidemiological model, constrained by observations, to assess the sensitivity of future SARS-CoV-2 disease trajectories to local climate conditions. We find this sensitivity depends on both the susceptibility of the population and the efficacy of non-pharmaceutical controls (NPIs) in reducing transmission. Assuming high susceptibility, more stringent NPIs may be required to minimize outbreak risk in the winter months. Our results imply a role for meteorological forecasts in projecting outbreak severity, however, reducing uncertainty in epidemiological parameters will likely have a greater impact on generating accurate predictions and reflects the strong leverage of NPIs on future outbreak severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available. https://github.com/CSSEGISandData/COVID-19